Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Kaitlin Colella

Physician Assistant, Medical Windermere, FL Physician Assistant

NPI 1437570827 CMS profile 10668615

5151 Winter Garden Vineland Rd Ste 107, Windermere, FL 34786

Open in the dashboard

General payments

$17,668

245 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kaitlin Colella of Windermere, FL is reported in the CMS Open Payments database as having received $17,668 across 245 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,142 10
2024 General $1,046 14
2023 General $1,130 40
2022 General $1,975 54
2021 General $12,376 127

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kaitlin Colella
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Kaitlin Colella were reported at $1,142. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Kaitlin Colella Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $12,376 $156 $41–$563 $132
2022 $1,975 $185 $55–$649 $149
2023 $1,130 $199 $58–$717 $160
2024 $1,046 $206 $62–$740 $164
2025 $1,142 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. QOL Medical, LLC $11,122 29 payments
  2. AbbVie, Inc. $1,321 72 payments
  3. Salix Pharmaceuticals, a division of Bausch Health US, LLC $1,190 37 payments
  4. Janssen Biotech, Inc. $1,009 21 payments
  5. Takeda Pharmaceuticals U.S.A., Inc. $364 15 payments
  6. Ardelyx, Inc. $340 3 payments
  7. Pfizer Inc. $261 14 payments
  8. Intercept Pharmaceuticals, Inc. $235 6 payments
  9. Celgene Corporation $196 9 payments
  10. Genzyme Corporation $156 3 payments
  11. Other $1,476 36 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $10,688 18 payments
  2. Food and Beverage $6,377 221 payments
  3. Education $362 4 payments
  4. Consulting Fee $225 1 payment
  5. Travel and Lodging $17 1 payment
Products named General payments · program years 2021–2025
  1. Sucraid $10,920 25 payments
  2. XIFAXAN $799 20 payments
  3. STELARA $752 20 payments
  4. TREMFYA $392 3 payments
  5. SKYRIZI $374 13 payments
  6. TRULANCE $362 19 payments
  7. HUMIRA $355 24 payments
  8. IBSRELA $340 3 payments
  9. ENTYVIO $338 14 payments
  10. RINVOQ $304 21 payments
  11. Other $2,959 119 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 6 billing codes

Paid by Medicare

$12,107

Medicare's payments for the services billed

Medicare patients

115

Average age 75

Services billed

192

64 women, 51 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Chronic kidney disease 58%
Diabetes 57%
Arthritis 57%
Ischemic heart disease 54%
Heart failure 50%
Depression 50%
Atrial fibrillation 38%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
IBSRELA
  • Ardelyx, Inc. $242
$242 — —
Sucraid
  • QOL Medical, LLC $161
$161 — —
DUPIXENT
  • GENZYME CORPORATION $156
$156 — —
TREMFYA
  • Janssen Biotech, Inc. $125
$125 — —
VEGZELMA
  • Celltrion USA Inc. $97
$97 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

245 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record